New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:14 EDTGALEGalena presents GALE-301 Phase 1 data
Galena announced that data from the company's Phase 1 study with GALE-301, or Folate Binding Protein, was presented at the American Society of Clinical Oncology 50th Annual Meeting. The poster entitled, "Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy," was presented during the Gynecologic Cancer General Poster Session. Overall, 30 patients were enrolled in the Phase 1 trial. Of 14 control patients, 50% have recurred. Of 16 vaccinated patients, 25% have recurred after completing the primary vaccine series and 12.5% recurred prior to completing the PVS, and one patient withdrew. Of note, no recurrences have been seen in the optimal dose cohort of 1000 mcg E39. The vR patients displayed lower mean delayed type hypersensitivity reactions as well as lower local reactions at every measured time point. The company said, "These promising initial results demonstrate the vaccine is dose responsive with the immune system and we are encouraged about the potential for this compound to prevent recurrence in women suffering from high risk gynecological cancers where current treatment options are limited. The data from this study served as the basis for advancing GALE-301 into its ongoing Phase 2 trial that includes a booster regimen. We expect enrollment in this trial to complete shortly, ahead of schedule."
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
07:07 EDTGALEGalena announces publication of two abstracts at ASCO
Galena Biopharma announced two abstract publications at the American Society of Clinical Oncology, or ASCO, 2015 Annual Meeting. "The two abstracts published by ASCO provide meaningful advancements for both of our cancer immunotherapy programs, NeuVax and GALE-301," said Mark Schwartz, Ph.D., president and CEO. "The use of Leica's Bond Oracle HER2 IHC system ensures we have enrolled the specified HER2 1+/2+ patients for our Phase 3 NeuVax™ PRESENT trial and moves us further down the path of providing targeted, personalized medicine for these women. Meanwhile, the published preliminary data from our GALE-301 program is quite promising as it shows significant reduction of recurrences with our vaccine. We expect to present more mature data at a scientific conference this Fall, and we are currently evaluating the next steps to potentially advance GALE-301 into a randomized late-stage trial to prevent recurrence in ovarian and endometrial cancers."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use